News #ECTRIMS2016 – Biogen to Unveil Study into Economic and Human Costs of MS #ECTRIMS2016 – Biogen to Unveil Study into Economic and Human Costs of MS by Patricia Silva, PhD | September 12, 2016 Share this article: Share article via email Copy article link At theĀ European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking placeĀ inĀ London on Sept. 14ā17, Biogen will present the Multiple Sclerosis Cost of Illness study, based on research intoĀ more than 16,000 MS patients throughout Europe. The study builds on data from a leading 2005 study that also examined the economic burden of the disease on MS patients and their caregivers. This new study is led by Gisela Kobelt, PhD, who also authored the 2005 report. In addition to presenting study findings, Kobelt will lead a workshop open toĀ patient groups in whichĀ she will discuss those findings and their insights together with the studyās clinical advisers. Data will be presented in two poster sessions: āCognition, Fatigue and Health-Related Quality of Life in Patients with Multiple Sclerosis: Results from a European-Wide Study,ā and āInability to Work and Need for Social and Family Support Drive Costs in Multiple Sclerosis.ā Both posters will be presented Ā on Friday, Sept. 16. āWe look forward to hearing from the patient community in our upcoming ECTRIMS workshop on the burden of illness in MS,ā Ralph Kern, MD, senior vice president at Biogenās Worldwide Medical department, said in a news release. āWe encourage an open discussion about how the community can apply the main findings of the study to engage and educate researchers, governments, and policymakers around the issues most critical to patients, and, ultimately, identify new ways to improve outcomes in the treatment of MS,ā he added. In addition to the Cost of Illness Study, Biogen will present data on several of its MS treatments. New data onĀ Tecfidera (dimethyl fumarate) demonstrated thatĀ it shows sustained effects in both newly diagnosed and previously treated relapsing MS patients. Long-term data also confirms that up to nine years of treatment with Tecfidera is safe. Biogen will also show data comparing Tecfidera to the other common MS treatments. Additional data on the newly approved MS drug Zinbryta (daclizumab), a once-monthly injection under the skin that patients administer themselves, will also be presented. Among other data, a comparison with intramuscular interferon beta-1a treatment will be shown. New findings related to both old and new drugs, such as Tysabri (natalizumab ), Plegridy (peginterferon Beta-1a), Fampyra (prolonged-release fampridine tablets), and the experimental drug Opicinumab, will alsoĀ be covered in variousĀ presentations at the meeting. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Biogen, ECTRIMS2016, Tecfidera, Tysabri, ZINBRYTA
March 28, 2024 Columns by Benjamin Hofmeister Multiple sclerosis awareness is for people with MS, too
March 28, 2024 News by Lindsey Shapiro, PhD Restoring ‘lost’ pathway of neuroprotection benefits MS mice